OLCC Expands Recall of Cannabis E-Cig Pods in Oregon

Feb.16.2023
OLCC Expands Recall of Cannabis E-Cig Pods in Oregon
Oregon's OLCC has expanded its recall of cannabis e-pods due to the presence of synthetic cannabinoids, affecting 7,000 units.

Portland, Oregon - The Oregon Liquor Control Commission (OLCC) has announced an expansion of the recall of marijuana electronic pods.


This recall was originally announced in January 2023.


The OLCC's ongoing investigation and evaluation has found that three batches of electronic cigarette products appear to contain prohibited additives. It states that these products do not meet national standards as they contain synthetic CBN and CBC, which produce sensory effects that are distinctly different from the psychoactive effects of tetrahydrocannabinol (THC). Ohio law prohibits electronic cigarette pods from containing synthetic cannabinoids and the synthesized CBC does not meet OLCC's requirements for non-cannabis additives.


This recall involves pods sold under the Firefly Extracts or Smoke-Rite Wellness brands. The OLCC stated that 7,000 units from the recalled batches have been sold, while approximately 500 units are still present in the market.


These recalled products were produced in a factory licensed by OLCC.


The OLCC has released a list of recalled products.


Product names, production dates, and start of sales for several Firefly pods have been reported by the OLCC. The "Purple Kush 8:1" pod with label ID 5658 was produced on May 27, 2022, and went on sale on June 21, 2022. The "Suver Haze" pod with the same label ID was produced on May 24, 2022, and began selling on March 11, 2022. The "T-1" or "High CBD 8:1" pod with label ID 5658 was produced on May 19, 2022, and has been available since that date. The "Cherry Wife 8:1" or "High CBD Blend 8" pod with label ID 5658 was produced on September 9, 2021, and went on sale on February 13, 2022. The "Cherry Wife 1:1" or "High CBD Blend 1" or "High CBD Blend 1:1" pod with label ID 5658 or 344 was produced on September 9, 2021, and began selling on October 23, 2021. The "Cherry Wife 2:1" or "High CBD Blend 2" or "High CBD Blend 2:1" pod with the same label ID was produced on September 9, 2021, and went on sale on December 12, 2021. The "Cherry Wife 10:1" or "High CBD Blend 10" or "High CBD Blend 10:1" pod with label ID 5658 or 344 was produced on July 27, 2021, and began selling on August 16, 2021. The "El Jefe" or "High CBD Blend 0" pod with label ID 5658 was produced on July 15, 2021, and went on sale on July 28, 2021. The "Sour Space Candy" pod with the same label ID was produced on May 3, 2021, and began selling on May 9, 2021. The "High CBD Blend 0" pod with label ID 5658 was produced on December 1, 2020, and became available on December 24, 2020. The OLCC has instructed those who purchased these recalled products to dispose of them, but has not received any health-related complaints related to their use.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

PMI Q2 Revenue Rises 10.4% as IQOS and VEEV Expand, U.S. ZYN Growth Slows
PMI Q2 Revenue Rises 10.4% as IQOS and VEEV Expand, U.S. ZYN Growth Slows
Philip Morris International’s second-quarter net revenues rose 10.4% to a record $11.19 billion, as heated tobacco and e-vapor expanded across international markets. IQOS remained the main smoke-free growth engine, while VEEV shipments jumped 55.1%. In the United States, however, ZYN shipments increased just 1.8% and consumer offtake was broadly flat to slightly higher. Cigarette volumes also rose, showing that PMI’s transformation is advancing, but growth is becoming increasingly uneven across categories and markets.
PMI
Jul.22
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
According to VitalLaw on August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit vacated an FDA marketing denial order (MDO) against NicQuid LLC, ruling that the agency’s comparative-efficacy standard for electronic nicotine delivery system (ENDS) applications had become a substantive rule requiring notice-and-comment rulemaking under the Administrative Procedure Act (APA). The court did not reject FDA’s authority to compare the public health benefits and risks of flavored vapes, but held that the agency could not establish a broadly binding standard through informal adjudications. The case was remanded to FDA for further proceedings.
Aug.28
China’s Jiangsu Tobacco Monopoly Bureau and Drug Regulator Target Illegal Vape Sales Disguised as Medical Devices, Define Six Violations
China’s Jiangsu Tobacco Monopoly Bureau and Drug Regulator Target Illegal Vape Sales Disguised as Medical Devices, Define Six Violations
China’s Jiangsu Tobacco Monopoly Bureau and Jiangsu Provincial Medical Products Administration have issued a joint notice targeting illegal production and sales of vape products disguised as medical devices. The notice identifies six categories of violations, including obtaining medical licenses through false materials, misusing medical device credentials, expanding production beyond approved scopes, and using medical device-related online platforms to promote or sell vape products. The action is based on China’s tobacco and medical device regulations and aims to strengthen vape oversight and consumer protection.
Aug.04
China’s Jinhua Tobacco Launches CNY 2.7 Million Procurement for E-Cigarette Violation Lead Monitoring Services
China’s Jinhua Tobacco Launches CNY 2.7 Million Procurement for E-Cigarette Violation Lead Monitoring Services
Jinhua Tobacco, a municipal tobacco company in China’s Zhejiang province, has launched a public tender for e-cigarette-related violation lead monitoring and consulting services. The project is valued at CNY 2.7 million and covers data resource integration and analytical consulting services for 36 months from contract signing. The procurement reflects the use of external data and analysis services to support local tobacco companies’ market oversight activities related to e-cigarettes.
Aug.07
Malaysia’s Vape Rules Face Review as Health Minister Dzulkefly Ahmad Addresses Dropped Nicotine Appeal
Malaysia’s Vape Rules Face Review as Health Minister Dzulkefly Ahmad Addresses Dropped Nicotine Appeal
According to Free Malaysia Today on August 26, 2026, Malaysia’s Health Minister Dzulkefly Ahmad said the Health Ministry would explain the government’s decision to withdraw its appeal against a High Court ruling involving the exemption of liquid nicotine used in vape products from the Poisons List. The High Court previously ruled that the exemption decision was irrational. Dzulkefly said withdrawing the appeal did not mean the government would stop regulating vaping, and that future regulatory approaches would continue under existing legal frameworks.
Aug.28
Product | PMI Japan Launches SENTIA Passion Fruit Capsule, Expanding the IQOS ILUMA Flavor Portfolio
Product | PMI Japan Launches SENTIA Passion Fruit Capsule, Expanding the IQOS ILUMA Flavor Portfolio
Philip Morris Japan (PM Japan) has introduced SENTIA Passion Fruit Capsule, a new tobacco stick designed for the IQOS ILUMA heated tobacco platform. Featuring a crush-activated capsule, the product combines menthol with passion fruit flavor to provide an additional flavor experience. The product launched in Japan from August 3, 2026, through IQOS official channels, convenience stores and tobacco retailers.
Aug.04